RecruitingHCC - Hepatocellular Carcinoma
Defining the Ablative Dose for Y-90 TARE
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study is being done to help doctors improve how they treat liver tumors that cannot be removed by surgery or treated with standard ablation techniques. The researchers want to find out the best amount of radiation that needs to be delivered to completely destroy (or ablate) parts of the liver that have cancer.
Sponsor: Northwestern University
You may qualify if…
- ✓ Diagnosis of hepatocellular carcinoma (HCC), cholangiocarcinoma, or liver-dominant metastatic disease not amenable to surgical resection or ablation.
- ✓ Age ≥18 years.
- ✓ Child-Pugh class A or B liver function
- ✓ Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
- ✓ Adequate organ and bone marrow function as defined below:
- ✓ Leukocytes (WBC) ≥ 3,000/mcL
- ✓ Absolute neutrophil count (ANC) ≥ 1,500/mcL
- ✓ Hemoglobin ≥ 9 g/dL
You may not qualify if…
- ✕ Extrahepatic metastases.
- ✕ Pregnant or breastfeeding individuals.
- ✕ Tumors requiring treatment of more than two Couinaud segments.
- ✕ Known hypersensitivity to gadolinium-based contrast agents.
- ✕ Contraindications to MRI (e.g., incompatible pacemakers, claustrophobia unresponsive to sedation).
- ✕ Coagulopathy or clinical instability precluding angiographic intervention.
- ✕ Prisoners or individuals under legal custody.
- ✕ Adults unable to consent.
Where it's recruiting
Illinois
Chicago
Source: ClinicalTrials.gov · NCT07586046 · last updated 2026-09-15